切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2007, Vol. 01 ›› Issue (03) : 136 -138. doi: 10.3877/cma.j.issn.1674-0793.2007.03.004

论著

核蛋白受体对肝癌相关基因表达的信号转导调控
曹良启1, 陈锡林1, 汪谦1,()   
  1. 1.510080 广州,中山大学附属第一医院肝胆外科
  • 收稿日期:2007-06-06 出版日期:2007-10-01
  • 通信作者: 汪谦

Signal transduction regulation of nucleoprotein receptor in hepatocellular carcinoma

Liangqi CAO1, Xi-lin CHEN1, Qian WANG1,()   

  1. 1.Department of Hepatobiliary Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
  • Received:2007-06-06 Published:2007-10-01
  • Corresponding author: Qian WANG
引用本文:

曹良启, 陈锡林, 汪谦. 核蛋白受体对肝癌相关基因表达的信号转导调控[J/OL]. 中华普通外科学文献(电子版), 2007, 01(03): 136-138.

Liangqi CAO, Xi-lin CHEN, Qian WANG. Signal transduction regulation of nucleoprotein receptor in hepatocellular carcinoma[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2007, 01(03): 136-138.

目的

研究过氧化物酶体增殖物激活受体γ( PPARγ)和肿瘤抑制基因PTEN 在肝癌组织中表达的相关性,以及两种基因对人肝癌细胞BEL-7402 细胞生长的影响,并探讨其机制。

方法

分别应用RT-PCR 和Western blot 观察分析肝癌组织、癌旁组织以及肝癌细胞中PPARγ 和PTEN 的表达情况;应用MTT 法观察PPARγ 的合成配体罗格列酮(RGZ)对BEL-7402 细胞生长的影响。

结果

PPARγ mRNA 和PTEN mRNA 在肝癌组织较癌旁组织中表达是显著降低的,两者在肝癌组织中的表达呈正相关(r=0.774, P<0.01)。罗格列酮呈剂量和时间依赖性关系诱导PTEN 蛋白的表达和抑制BEL-7402 细胞的生长,此效应是通过PPARγ 通路活化实现的。

结论

PPARγ 和PTEN 在肝癌中表达呈正相关,RGZ 能够抑制BEL-7402 细胞的生长,此效应与RGZ 诱导PPARγ通路活化和PTEN 表达上调有关。

Objective

To investigate the correlation of PPARγ and PTEN mRNA expressions of hepatocellular carcinoma(HCC)tissue samples and the effect of both genes on human HCC cell line BEL-7402 cell growth.

Methods

RT-PCR analysis was performed to detect the mRNA expression levels of PPARγ and PTEN in 21 HCC samples. The expression of PTEN protein were assessed by Western blot analysis. The cell growth status of BEL-7402 cells was evaluated by MTT assay.

Results

The mRNA expression of PTEN and PPARγ decreased in HCC tissues, compared with adjacent nontumor liver tissues, and both the mRNA expressions indicated positive correlation (r =0.774, P<0.01).Rosiglitazone, as a synthetic ligands of PPARγ, inhibited BEL-7402 cell growth and increased PTEN protein expression by PPARγ pathway.

Conclusion

PTEN and PPARγ gene expression present positive correlation in HCC tissues. Rosiglitazone activate PPARγ pathway to increase PTEN expression, which may be the molecular mechanism of rosiglitazone-inhibited BEL-7402 cell growth.

1
Meirhaeghe A, Tanck MW, Fajas L, et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005, 85(2): 140-148.
2
Patel L, Pass I, Coxon P, et al. Tumor suppressor and antiinflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol, 2001, 11(10): 764-768.
3
Zhen MC, Huang XH, Wang Q, et al. Green tea polyphenol epigallocatechin-3- gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation.Acta Pharmacol Sin, 2006, 27(12): 1600-1607.
4
Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta -induced connective tissue growth factor expression. Acta Pharmacol Sin, 2006, 27(6):715-723.
5
Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol, 2001, 2(9): 533-543.
6
Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1,dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 1998, 273(22): 13375-13378.
7
Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.Hepatology, 2006, 43(1): 134-143.
8
Toyoda M, Takagi H, Horiguchi N, et al. A ligand for peroxisome proliferators activated receptor γ inhibitor cell growth and induces apoptosis in human liver cancer cells. Gut 2002, 50(4): 563-567.
9
Young PW, Buckle DR, Cantello BC, et al.Identification of highaffinity binding sites for theinsulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferatoractivated receptor gamma. J Pharmacol Exp Ther,1998,284(2):751-759.
10
Cao LQ,Chen XL, Wang Qian, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.Acta Pharmacol Sin,2007,28(6):879-887.
[1] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[2] 高金红, 陈玉梅, 郭韵. 基于King互动达标理论的心理疏导在腹腔镜肝癌切除术患者的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 517-520.
[3] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[4] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[5] 马立伟, 贾志强, 陈午盛, 邵明亮, 刘琼, 段玉松. CalliSpheres载药微球联合碘化油治疗肝癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 369-372.
[6] 胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[7] 王飞, 陈政, 余德才, 曹亚娟. 原发性肝癌合并门静脉高压症的微创手术治疗[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 306-310.
[8] 张敏, 朱建华, 缪雅芳, 郭锦荣. 菝葜皂苷元对肝癌HepG2细胞抑制作用的机制研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 328-335.
[9] 曾聿理, 雷发容, 肖慧, 邱德亮, 谢静, 吴寻. 氯普鲁卡因通过调控circRNA-ZKSCAN1表达抑制肝癌Huh-7细胞体外生长和转移的研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 220-228.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[12] 鲍乐, 刘颖, 王友彬, 陈龙, 朱玉芝, 梁爽, 权鹤太, 李鹏飞. 还阳通络灸在原发性肝癌介入治疗中的临床应用研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 197-202.
[13] 广东省护士协会介入护士分会, 广东省医师协会介入医师分会. 原发性肝癌低血糖患者护理规范管理专家共识[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 709-714.
[14] 韦巧玲, 黄妍, 赵昌, 宋庆峰, 陈祖毅, 黄莹, 蒙嫦, 黄靖. 肝癌微波消融术后中重度疼痛风险预测列线图模型构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 715-721.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要